FDMT Insider Trading

Insider Ownership Percentage: 7.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $5,009,402.30

4D Molecular Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at 4D Molecular Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10M$0$10MTotal Insider BuyingTotal Insider Selling

4D Molecular Therapeutics Share Price & Price History

Current Price: $6.35
Price Change: Price Increase of +0.42 (7.08%)
As of 01/6/2025 05:00 PM ET

This chart shows the closing price history over time for FDMT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
FebMarAprMayJunJulAugSepOctNovDecJan$5.93Closing price on 01/05/25:

SEC Filings (Institutional Ownership Changes) for 4D Molecular Therapeutics (NASDAQ:FDMT)

99.27% of 4D Molecular Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at FDMT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
202220232024$17Mbought$14MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4-$40M-$20M$0$20M$40MTotal InflowsTotal Outflows
4D Molecular Therapeutics logo
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
Read More on 4D Molecular Therapeutics

Today's Range

Now: $6.35
Low: $5.86
High: $6.65

50 Day Range

MA: $7.23
Low: $5.30
High: $8.83

52 Week Range

Now: $6.35
Low: $5.22
High: $36.25

Volume

998,049 shs

Average Volume

842,580 shs

Market Capitalization

$293.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.81

Who are the company insiders with the largest holdings of 4D Molecular Therapeutics?

4D Molecular Therapeutics' top insider shareholders include:
  1. Global Investors Lp Viking (Major Shareholder)
  2. David Kirn (CEO)
  3. Scott Bizily (Insider)
  4. Robert Young Kim (Insider)
  5. Jacob Chacko (Director)
Learn More about top insider investors at 4D Molecular Therapeutics.